Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
Takagi Y., Osaki H., Yamashita T., Kai Y.
View publication
-
Therapeutic Area
Glaucoma
-
Categories
Clinical development
-
Affiliations
Scientific Information Group, Santen Pharmaceutical Co., Ltd, Ofukacho Kita-ku, Osaka, Japan; Safety Vigilance Group, Santen Pharmaceutical Co., Ltd, Ofukacho Kita-ku, Osaka, Japan